Genomic medicine is rapidly transforming cancer care, and Edinburgh Genetics is at the forefront. Next-generation sequencing (NGS) allows us to analyse vast amounts of genetic data efficiently, revealing gene alterations linked to both inherited and sporadic cancers. This empowers treatment developers to develop personalised treatment plans and targeted therapies.

Our cutting-edge egSEQ library preparation and targeted sequencing solutions, combined with bioinformatics powered by the latest research, unlock possibilities for risk-based cancer screening and comprehensive genomic profiling.

We're actively researching and developing accessible In Vitro Diagnostics (IVD) and companion diagnostic solutions, utilising innovative technologies like cell-free DNA (cfDNA) and microRNA (miRNA) fuelling research efforts for a deeper understanding of cancer, leading to advancements in diagnosis, treatment, and ultimately, prevention.